SUPRANE Drug Patent Profile

When do Suprane patents expire, and when can generic versions of Suprane launch?

Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the desflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suprane

A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26^th, 2018.

Summary for SUPRANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	35
Patent Applications:	2,950
Drug Prices:	Drug price information for SUPRANE
What excipients (inactive ingredients) are in SUPRANE?	SUPRANE excipients list
DailyMed Link:	SUPRANE at DailyMed

See drug prices for SUPRANE

Recent Clinical Trials for SUPRANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute, Egypt	N/A
Sefako Makgatho Health Sciences University	N/A
GAMZE PİRİNÇ ŞAŞIOĞLU	N/A

See all SUPRANE clinical trials

Pharmacology for SUPRANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Paragraph IV (Patent) Challenges for SUPRANE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRANE	Inhalation	desflurane	99.9%	020118	1	2008-09-11

US Patents and Regulatory Information for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes

Expired US Patents for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	4,762,856*PED
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	5,617,906*PED

International Patents for SUPRANE

See the table below for patents covering SUPRANE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	3324750
Norway	880434
South Korea	100198205
South Korea	910006888
Spain	2151485
Denmark	0568564
Australia	1114388

Supplementary Protection Certificates for SUPRANE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0285237	94C0006	France		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0285237	95C0008	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107

Market Dynamics and Financial Trajectory for SUPRANE

Last updated: March 21, 2026

What is SUPRANE and its core uses?

SUPRANE (desflurane) is a volatile inhalation anesthetic used primarily for induction and maintenance of general anesthesia. It has a rapid onset and recovery profile due to its low blood-gas partition coefficient. Approved by the FDA in 1992, SUPRANE is marketed by Baxter International, now part of Baxter BioPharma Solutions.

What are the key drivers influencing SUPRANE's market position?

Market Size and Segment Composition

The global inhalation anesthetic market was valued at approximately \$600 million in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030, driven by increased surgical procedures worldwide.

Competition and Product Differentiation

Supurane faces competition from other volatile anesthetics such as sevoflurane (Ultane), isoflurane, and newer agents like xenon. However, its fast onset, ease of titration, and quick recovery make it favored in certain hospital settings.

Usage Trends

The rising number of surgeries, aging populations, and expanding outpatient surgery centers favor inhalation anesthetic demand. Conversely, concerns over environmental impact and the advent of total intravenous anesthesia (TIVA) shift some procedures away from inhalation agents.

Regulatory Environment

Worldwide, regulatory policies on environmental emissions of anesthetics influence market dynamics. The Kyoto Protocol and subsequent regional policies aim to reduce gases with high global warming potential, including desflurane.

Environmental Impact and Sustainability Policies

Desflurane has a GWP (global warming potential) of approximately 2540 over 100 years, higher than sevoflurane (GWP ~130). Several regions, including the European Union, are pushing for restrictions on high-GWP anesthetics, impacting future sales volumes.

How do recent market developments shape SUPRANE's financial outlook?

Patent and Regulatory Status

SUPRANE was not under patent protection after 2010, exposing it to generic competition. Patent expirations diminish pricing power, putting pressure on profit margins.

Price Trends

Average hospital procurement prices for SUPRANE have declined by 15% over the past five years due to increased competition and generic entries. The current price per vial averages around \$70, compared to \$85 five years prior.

Revenue Performance

Baxter International's sales of SUPRANE have shown stagnation or slight decline, with global revenues estimated at \$130 million in 2022, representing approximately 5-6% of Baxter's overall anesthesia product segment.

Market Penetration and Adoption

Supurane's adoption rate varies by region; higher in North America and Europe due to established hospital protocols, but limited growth prospects in emerging markets because of cost constraints and environmental concerns.

Impact of Environmental Regulations

Growing restrictions focused on anesthetic gases raise concerns over SUPRANE's future sales, especially in Europe. Potential regulations could limit use or increase costs through required capture or scrubbing systems.

What are future opportunities and risks?

Opportunities

• Developing delivery systems that reduce environmental impact.
• Expanding use in outpatient and minimally invasive procedures.
• Entering markets with less stringent environmental regulations or developing regulatory exemptions.

Risks

• Substitution by TIVA methods or newer inhalation agents with lower GWP.
• Regulatory restrictions on GWP and carbon emissions.
• Market shrinkage driven by environmental policies and sustainability initiatives.

What is the financial outlook trajectory?

Timeline	Key Indicators	Forecasts
2023-2025	Slight decline in sales volume, price stabilization	Revenues estimated around \$125 million, a 4% decline from 2022 levels
2026-2028	Market contraction under environmental restrictions	Potential 10-15% revenue decline if regional policies remain restrictive
2029+	Innovation or substitution impact	Volumes could decline further unless new formulations or delivery systems emerge

Key Takeaways

• SUPRANE remains a key inhalation anesthetic but faces pressure from environmental policies and patent expirations.
• Market growth is modest, driven by surgical volume increases, but faces headwinds from environmental regulation.
• Price erosion and competition limit revenue growth prospects.
• Future profitability hinges on innovation, environmental mitigation, and regional regulatory landscapes.

FAQs

1. How does SUPRANE compare environmentally to other anesthetics?
   SUPRANE has a higher GWP (~2540) than alternatives like sevoflurane (~130), raising environmental concerns, especially in regions restricting high-GWP gases.

2. What is the primary competition for SUPRANE?
   Sevoflurane (Ultane) dominates the market due to lower GWP and similar clinical profile, along with isoflurane and newer agents like xenon, which are less common.

3. How will environmental regulations impact SUPRANE’s sales?
   Restrictions on high-GWP gases could cause a decline in use, increase costs for hospital systems needing emission control, and accelerate substitution with TIVA or low-GWP agents.

4. What is the current market share of SUPRANE?
   SUPRANE holds approximately 25-30% of the global inhalation anesthetic market, mostly in developed regions.

5. Are there technological innovations that could revive SUPRANE's market?
   Development of delivery systems reducing gas emissions, or formulations with lower GWP, could mitigate regulatory impacts and sustain demand.

---

References

[1] MarketResearch.com. (2022). Global inhalation anesthetic market report.
[2] European Commission. (2021). Regulations on environmental impact of anesthetic gases.
[3] Baxter International Inc. (2022). Annual report.
[4] GWP values for anesthetic gases. (2018). Environmental Science & Technology.